Table 3 : Reported toxicities with concurrent chemoradiotherapy among group 1 (cisplatin treated patients)
and group II (cisplatin with paclitaxel treated patients).

Variables	Group 1 N=25 (%)				Group II N=30 (%)
	G1	G2	G3	G4	G1	G2	G3	G4
Early toxicity
Anemia	3 (12%)	5 (20%)	0 (0%)	0	6 (20%)	5 (16.7%)	1 (3.3%)	1 (3.3%)
Leucopenia	4 (16%)	2 (8%)	1 (4%)	0	3 (10%)	2 (6.7%)	1 (3.3%)	0
Thrombocytopenia	1 (4%)	1 (4%)	0 (0%)	0	3 (10%)	2 (6.7%)	0	0
Diarrhea	10 (40%)	3 (12%)	1 (4%)	0	11 (36.7%)	5 (16.6%)	1 (3.3%)	0
Vomiting	12 (48%)	5 (20%)	0	0	13 (43.3%)	7 (23.3%)	2 (6.7%)	0
Proctitis	15 (60%)	3 (12%)	0	0	10 (33.3%)	2 (6.7%)	0	0
Dysuria	8 (32%)	8 (32%)	2 (8%)	0	9 (30%)	8 (26.6%)	3 (10%)	0
Frequency/urgency	6 (24%)	5 (20%)	2 (8%)	1 (4%)	10 (33.3%)	7 (23.3%)	4 (13.3%)	1
Radiation dermatitis	5 (20%)	1 (4%)	0	0	4 (13.3%)	1 (3.3%)	0	0
Increased creatinine	5 (20%)	1 (4%)	0	0	3 (10%0	1 (3.3%)	0	0
Increased bilirubin	0	0	0	0	0	0	0	0
Increased liver enzymes	0	0	0	0	0	0	0	0
Allergy	1 (4%)	0	0	0	2 (6.7%)	0	0	0
Hearing impairment	1 (4%)	0	0	0	1 (3.3%)	0	0	0
Cardiovascular arrhythmia	0	0	0	0	1 (3.3%)	1 (3.3%)	0	0
Late Toxicity
Proctitis	4 (16%)	1 (4%)	0	0	3 (10%)	1 (3.3%)	0	0
Dysuria	6 (24%)	4 (16%)	1 (4%)	0	6 (20%)	3 (10%)	1 (3.3%)	0
Frequency/urgency	15 (60%)	2 (8%)	0	0	9 (30%)	2 (6.7%)	0	0
Increased creatinine	2 (8%)	1 (4%)	0	0	1 (3.3%)	1 (3.3%)	0	0